Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $104 from $98 and keeps a Buy rating on the shares. The firm said its 4Q25 earnings delivered a slight top-line beat but was otherwise uneventful following the company’s recent announcement of the acquisition of Amicus (FOLD) and updates at the January investor conference.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target raised to $94 from $90 at Bernstein
- BioMarin price target lowered to $86 from $106 at Guggenheim
- BioMarin price target lowered to $55 from $60 at H.C. Wainwright
- BioMarin Earnings Call Highlights Growth, Pipeline, Deals
- BioMarin price target lowered to $95 from $98 at Oppenheimer